Tissue and plasma tumor mutation burden (TMB) as predictive biomarkers in the CO. 26 trial of durvalumab plus tremelimumab (D plus T) versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).

作者： Jonathan M Loree , James T Topham , Hagen F Kennecke , Harriet Feilotter , Faeze Keshavarz-Rahaghi